Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. IMRN
IMRN logo

IMRN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.875
Open
0.838
VWAP
0.83
Vol
33.78K
Mkt Cap
7.11M
Low
0.786
Amount
28.11K
EV/EBITDA(TTM)
--
Total Shares
8.08M
EV
-195.72K
EV/OCF(TTM)
--
P/S(TTM)
1.02
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Show More

Events Timeline

(ET)
2025-12-03
10:20:00
Trump Administration Injects $150M into xLight
select
2025-12-03
06:10:00
Immuron Signs New Research Agreement with Naval Medical Research Command
select
2025-11-05 (ET)
2025-11-05
06:23:30
Immuron Receives FDA Approval for IND of IMM-529
select
2025-10-08 (ET)
2025-10-08
06:04:54
Immuron Files IND Application with FDA for Clinical Development of IMM-529
select
2025-10-02 (ET)
2025-10-02
06:19:13
Immuron Provides Update on Ongoing Projects
select
2025-08-27 (ET)
2025-08-27
05:17:06
Immuron Forms Partnership with InvestorHub
select
2025-07-17 (ET)
2025-07-17
06:04:31
Immuron says FY25 global sales exceed projection, up 49% over prior year
select
2025-03-05 (ET)
2025-03-05
06:03:06
Immuron partners with Calmino to distribute ProIBS in Australia, New Zealand
select
2025-01-17 (ET)
2025-01-17
05:09:23
Immuron reports strong sales growth of Travelan
select
2025-01-15 (ET)
2025-01-15
05:02:19
Immuron announces research collaboration agreement with Monash University
select

News

Newsfilter
8.5
03-05Newsfilter
Immuron CEO to Present at Coffee Microcaps Conference
  • CEO Presentation Opportunity: Immuron's CEO Steven Lydeamore will present at the Coffee Microcaps Conference on March 5, 2026, showcasing the company's latest developments and strategies, which is expected to attract investor interest and enhance the company's visibility.
  • Travelan® Product Introduction: Travelan®, an oral immunotherapy, effectively reduces the risk of travelers' diarrhea and is registered as a therapeutic product in Australia while being sold as a health product in Canada and the U.S., highlighting its market potential and international strategy.
  • IMM-529 Development Progress: Immuron is developing IMM-529 as an adjunctive therapy for preventing and treating recurrent Clostridioides difficile infections, with preliminary clinical results showing significant efficacy in disease prevention and treatment, potentially transforming antibiotic treatment paradigms.
  • ProIBS® Market Outlook: Immuron has signed an exclusive distribution agreement with Calmino Group for ProIBS®, a medical device for treating irritable bowel syndrome, which is expected to meet the demand for long-term effective treatments in the Australian and New Zealand markets, indicating substantial market potential.
seekingalpha
9.5
02-25seekingalpha
Immuron Reports Record Half-Year Sales of A$4.2 Million
  • Sales Performance Growth: Immuron achieved record sales of A$4.2 million in the first half of FY25, reflecting a 5% increase, indicating a stable growth trend in the market despite economic uncertainties.
  • Earnings Per Share Situation: The company reported an EPS of -A$0.70, highlighting ongoing challenges in achieving profitability despite sales growth, which may impact investor confidence moving forward.
  • Investor Conference Participation: Immuron presented its business strategy at the Emerging Growth Conference, aiming to attract potential investors and enhance market visibility, demonstrating the company's proactive approach to future growth.
  • Historical Financial Data Review: Analyzing historical financial data allows investors to better understand Immuron's performance fluctuations and future growth potential, aiding in more informed investment decisions.
Newsfilter
9.5
02-25Newsfilter
Immuron Reports Strong H1 FY26 Financial Results and Strategic Developments
  • Consistent Revenue Growth: Immuron's H1 FY26 sales reached AUD 4.2 million, reflecting a 17% year-over-year increase, particularly driven by strong momentum in the U.S. market, indicating enhanced competitiveness on a global scale.
  • Strong Cash Position: The company holds AUD 10 million in cash to fund operations, including AUD 7.3 million raised at an average price of AUD 0.0803 per share, providing a solid financial foundation for future R&D and market expansion.
  • Validated Platform with New Targets: Immuron's 'Hyper-Immune' platform has proven successful in treating traveler's diarrhea (Travelan®) and is now targeting high-value clinical applications like C. difficile (IMM-529), showcasing the versatility and market potential of its technology.
  • Strategic Partnerships: The company has opted to pursue partnerships to advance the clinical programs for Travelan® (IMM-124E) and IMM-529, with IMM-124E qualifying for an end-of-Phase 2 meeting with the FDA, indicating significant progress in its clinical development.
Benzinga
9.5
2025-12-16Benzinga
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
  • B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.

  • Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.

  • Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.

  • Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.

Benzinga
2.0
2025-12-04Benzinga
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
  • UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.

  • Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.

  • Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.

Globenewswire
7.5
2025-12-03Globenewswire
Immuron Secures US Military Contract for New Oral Therapeutics Targeting Campylobacter and Shigella
  • New Contract Awarded: Immuron has secured a new contract with the U.S. Department of Defense to develop oral therapeutics targeting Campylobacter and Shigella, which is expected to significantly enhance gut health protection for U.S. military personnel.
  • Vaccine Development Progress: Collaboration with the Naval Medical Research Command and Walter Reed Army Institute of Research is advancing the development of new vaccines aimed at combating Shigella infections, which cause approximately 600,000 deaths annually worldwide.
  • Clinical Trial Update: Topline results from the Uniformed Services University's clinical trial evaluating the effectiveness of IMM-124E in maintaining gut health are anticipated soon, potentially providing critical data for future military applications.
  • Strong Market Demand: With an estimated 1.5 billion episodes of diarrhea occurring globally each year, particularly in developing countries, there is a pressing need for preventative treatments, positioning Immuron's new products to fill this market gap.

Valuation Metrics

The current forward P/E ratio for Immuron Ltd (IMRN.O) is -52.81, compared to its 5-year average forward P/E of -26.27. For a more detailed relative valuation and DCF analysis to assess Immuron Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-26.27
Current PE
-52.81
Overvalued PE
20.78
Undervalued PE
-73.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.07
Current PS
1.17
Overvalued PS
5.35
Undervalued PS
0.79

Financials

AI Analysis
Annual
Quarterly

Whales Holding IMRN

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Immuron Ltd (IMRN) stock price today?

The current price of IMRN is 0.8349 USD — it has decreased -5.11

What is Immuron Ltd (IMRN)'s business?

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

What is the price predicton of IMRN Stock?

Wall Street analysts forecast IMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Immuron Ltd (IMRN)'s revenue for the last quarter?

Immuron Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Immuron Ltd (IMRN)'s earnings per share (EPS) for the last quarter?

Immuron Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Immuron Ltd (IMRN). have?

Immuron Ltd (IMRN) has 7 emplpoyees as of March 09 2026.

What is Immuron Ltd (IMRN) market cap?

Today IMRN has the market capitalization of 7.11M USD.